Articles tagged with Combination Therapies
A new meta-analysis commissioned by WHO informs updated treatment guidelines for uncomplicated malaria in the first trimester of pregnancy. The study finds that artemether-lumefantrine is as safe and possibly more effective than non-artemisinin-based treatments, including quinine, with significant reductions in adverse pregnancy outcomes.
A new study finds that combining radiation with hormone therapy can improve outcomes for patients with oligometastatic prostate cancer. The trial showed that patients who received both treatments experienced longer progression-free survival and better testosterone levels after treatment.
Researchers have designed a smart cell-based delivery system to treat Alzheimer's disease by targeting multiple pathologies, reducing the risk of side effects. The system uses bio-synthesizable drugs and immune cells to deliver combination therapy that addresses all pathologies in a targeted manner.
A phase 2 study found that combining nivolumab and ipilimumab showed a high response rate with durable results for patients with advanced Merkel cell carcinoma. The addition of stereotactic body radiation therapy did not improve efficacy in this dual checkpoint inhibitor therapy.
A randomized phase III trial found that combination hormonal therapy, delivered for a finite treatment interval of 12 months, more durably suppresses PSA levels compared to hormone injections alone. The treatment approach improved disease progression in patients with high-risk biochemically relapsed prostate cancer.
Researchers at Mayo Clinic Comprehensive Cancer Center found that metabolic imaging, combined with traditional treatment response assessment methods, can provide critical information to guide therapy for pancreatic cancer patients. The use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant pr...
Researchers at Karolinska Institutet have developed a potential curative treatment for neuroblastoma, using DHODH blockers in combination with chemotherapy to cure mice with the disease. The treatment has shown promising results and could improve survival rates for children with neuroblastoma.
Researchers have designed a phage combination therapy that precisely targets and suppresses gut bacteria associated with inflammatory bowel diseases (IBD). The team identified effective phages against IBD-contributing Kp strains, which attenuated inflammation and tissue damage in mice models.
The American Academy of Family Physicians has been awarded a $31 million funding to conduct a large-scale study on the comparative effectiveness of asthma treatments. The study will focus on inhaled steroids and specific antibiotics, alone or together, in over 3,000 patients with asthma aged 12 and over.
A new combination therapy using a plant virus and an antibody activates natural killer cells to target and destroy cancer cells. The therapy eliminates all tumors and prevents their recurrence, resulting in 100% survival in mouse models of colon cancer.
A combination of hormone therapy and pelvic lymph node radiation treatment significantly improved survival rates among patients with postoperative prostate cancer, extending their lives by nearly five years. This study published in The Lancet found that nearly 90% of clinical trial patients remained free from progression for five years.
A new combination therapy using a tumor-suppressing lipid molecule and an antibody for cytotoxic T-lymphocyte antigen 4 has been shown to significantly slow tumor growth and enhance the strength of tumor-attacking T cells in liver cancer. This promising approach offers hope for patients with limited treatment options.
Researchers load CAR-T cells with an oncolytic virus to target and kill solid cancer tumors, providing a potent immune response. The combination approach overcomes challenges in treating solid tumors with CAR-T cell therapy alone.
Researchers have found that treating prostate cancer cells with novel CDK8 and CDK19 inhibitors reduces their potential to migrate into surrounding structures. This suggests a promising approach to overcome resistance against anti-androgenic therapy, offering new therapeutic options for patients with advanced disease.
A novel nuclear medicine combination therapy combining <sup> 177 </sup> Lu-PSMA-617 with idronoxil (NOX66) has been shown to be safe and effective in reducing PSA levels by over 50% in men with metastatic prostate cancer. The median overall survival was 19.7 months, suggesting potential for improved patient outcomes.
Researchers developed a compound consisting of insulin bound to an antioxidant group, improving glucose consumption and brain function in mice with type 1 diabetes. The combination therapy showed better cognitive performance than individual treatments alone.
Researchers at Ben-Gurion University have developed a potential treatment combination for advanced head and neck cancer, which shows promise in pre-clinical models. The therapy involves blocking a specific signaling pathway and sensitizing tumors to immunotherapy, resulting in the disappearance of tumors.
A Phase 3 clinical study of selinexor as maintenance therapy for advanced or recurrent endometrial cancer showed a 30% decrease in hazard for progression or death compared to the placebo-controlled group. Patients with functional p53 genes saw the most pronounced effect, with median progression-free survival at 10 months longer.
A Phase 1 clinical trial showed CBM588 significantly improved progression-free survival in patients with metastatic kidney cancer when combined with immunotherapy. The treatment also increased response rates compared to immunotherapy alone, with no significant differences in toxicity.
The article suggests a potential treatment option for COVID-19 by targeting SARS-CoV-2's interaction with ACE2 receptors. Combining DPP4 inhibitors and spironolactone may mitigate COVID-19 complications and infections without adverse side effects.
Researchers at the University of Helsinki found that a cellular stress state predicts a poor chemotherapy response in ovarian cancer patients. High-stress tumours with an inflammatory microenvironment may resist chemotherapy, making combination therapies a potential solution.
Researchers found that starting combined antiretroviral therapy against simian immunodeficiency virus two weeks after infection significantly reduced chronic immune activation, SIV replication, and latent TB reactivation. This study contributes to the growing evidence on the complex interaction between HIV and tuberculosis.
Researchers at Rosalind Franklin University have identified a new therapeutic approach for treating cystic fibrosis. The treatment uses antisense oligonucleotides to restore CFTR function by removing stop mutations. This strategy has shown promise in treating CF patients with class I mutations and similar types of mutations.
Research found marked decreases in orphanhood, especially double orphanhood, among adolescents in Rakai, Uganda, corresponding with the rise of antiretroviral therapy and male medical circumcision. The study suggests that HIV combination prevention reduces mortality among adults and orphanhood among their adolescent children.
Patients treated with pyrotinib plus capecitabine had a lower risk of death and longer progression-free survival compared to those receiving lapatinib plus capecitabine. Pyrotinib is an irreversible tyrosine kinase receptor inhibitor targeting HER2, EGFR, and HER4.
In a phase III trial, elacestrant showed significant benefits in decreasing death or disease progression and increasing progression-free survival compared to standard of care. The treatment was well-tolerated with manageable side effects, offering hope for patients with ER-positive/HER2-negative metastatic breast cancer.
A recent study led by Okayama University scientists found that metformin activates a subset of immune cells called CD8+ T-lymphocytes to attack and kill tumor cells. The study revealed that metformin increases the production of reactive oxygen species in these cells, which activates growth pathways and allows for proliferation.
A Phase II study shows that combination treatment with nivolumab and ipilimumab improves overall survival in patients with asymptomatic melanoma brain metastases, with an overall survival rate of 71.9% at three years. The treatment demonstrates durable responses, even in symptomatic patients.
Patients with advanced renal cell carcinoma treated with checkpoint inhibitor combination nivolumab plus ipilimumab experienced longer treatment-free survival compared to those receiving targeted therapy sunitinib. The analysis revealed significant differences in how patients spent their overall survival time between the two treatments.
Researchers found that certain T cells stop working before entering the tumor due to changes in gene expression, making ICB therapies less effective. Combining ICB with other forms of immunotherapy targeting different aspects of T cell function may improve response rates for non-small cell lung cancer patients.
Researchers at the University of Alabama at Birmingham have developed a method to identify non-responding tumors using hypoxia imaging, which shows promise for improving response rates. Investigational new drug evofosfamide was found beneficial in treating hypoxic tumors with immunotherapy.
Researchers conducted genomic evaluations of advanced malignancies to develop matched, individualized combination therapies. The study found that precision cancer therapy improved median overall survival rate by 3.9 months compared to standard care.
A nationwide team of researchers will investigate epigenetic therapies for cancer, with a focus on exploring new targets and investigating novel combinations. The project aims to improve current epigenetic therapies and enhance existing approaches such as immunotherapy.
The KEYNOTE-716 trial shows that adjuvant pembrolizumab significantly prolongs recurrence-free survival and halves distant recurrences in stage II B/C melanoma patients. This suggests that patients with high-risk stage II melanoma should be offered adjuvant therapy.
Scientists have developed a new therapy that combines bacteriophages with antibiotics to treat antibiotic-resistant infections, specifically targeting Mycobacterium abscessus. The treatment, using the bacteriophage 'Muddy', showed significant improvement in survival rates and severity of infections when paired with rifabutin, demonstra...
Researchers at McGill University identified proteins that drive cancer stem cells in brain tumours. Targeting the protein galectin1 may provide a more effective treatment for glioblastoma when combined with radiation therapy. The study found significant improvement in tumour response to radiation therapy, resulting in expanded lifespan.
Despite its promise, cancer immunotherapy faces several hurdles, including limited efficacy and variable outcomes. Researchers are exploring new therapeutic targets and combination strategies to overcome resistance and improve patient outcomes.
Researchers at WashU Medicine have identified an antibody that is highly protective at low doses against a wide range of viral variants. The antibody targets a part of the virus' spike protein that differs little across variants, making it unlikely to lose potency as the virus mutates.
Researchers at the University of Kentucky have demonstrated the potential benefit of using an inhibitor of the PI3K/mTOR pathway to increase the toxic effect of radiation therapy in models of gastroenteropancreatic neuroendocrine tumors. The study showed that combining radiation therapy with a PI3K/mTOR inhibitor produced a synergistic...
A team from UNIGE and HUG used information theory to study the molecular regulations behind cancer cell adaptation to targeted therapies. They found that a large reversible component of resistance exists, which can be modulated by therapeutic combinations.
The study found that combining mTORC1 and PLK1 inhibitors showed high antitumor activity in NSCLC, with synergistic effects observed. The combination may target specific biomarkers of resistance to Pi3K-based monotherapies, offering a promising therapeutic approach.
Researchers identified T cells that are paralyzed and ineffective in preventing LCH lesion formation, instead being tricked into entering an exhausted state. A new therapeutic option combining immunotherapy targeting PD-1 receptors with MAPK inhibition demonstrates promising results.
Researchers created a novel platelet-based delivery system to target and penetrate tumors, combining photothermal therapy and immunotherapy. The biomimetic formulation demonstrated potent therapeutic effects against multiple types of cancer in murine models.
Researchers at Moffitt Cancer Center found that sequential treatment with immunotherapy followed by BRAF and MEK inhibitors promotes anti-tumor immunity and suppresses signaling that leads to drug resistance. The study suggests that this approach may be a potential treatment option for patients with melanoma.
The NEOSTAR trial found that combination therapy produced significant clinical benefits, including higher major pathologic response rates and enhanced tumor immune cell infiltration. The treatment also triggered immunological memory, which may translate to a reduced risk of tumor relapse.
A daily oral combination therapy has been found to be reliable, safe and effective for long-term treatment of uterine fibroids. The therapy, which combines relugolix with small doses of estrogen and synthetic progesterone, led to dramatic improvements in fibroid-related measures such as volume of menstrual blood loss and pain.
Researchers found that combining unmodified anti-tumor antibodies with MEKi and immune checkpoint blockade generated a robust adaptive anti-tumor response, sustained by immune checkpoint inhibition. This combination therapy showed improved therapeutic efficacy in mouse models of melanoma.
A Phase II trial conducted at the University of Texas M. D. Anderson Cancer Center found a 51% overall response rate in patients with BRAF-mutated cholangiocarcinoma treated with dabrafenib plus trametinib, providing a much-needed treatment option for patients with treatment-resistant advanced disease.
A Phase Ib/II trial found that adding idh1 inhibitor ivosidenib to either venetoclax or azacitidine resulted in a high complete remission rate of 78% overall, with 100% for treatment-naïve patients. The combination may ultimately lead to a new therapeutic regimen and tailored treatment options based on molecular profiles.
The American Thoracic Society recommends LABA/LAMA combination therapy for COPD patients experiencing dyspnea or exercise intolerance. This guideline also suggests considering triple therapy and withdrawing inhaled corticosteroids if no exacerbations occur.
Intratumoral SD-101 injection complements low-dose cyclophosphamide in boosting innate immunity and driving potent T cell-mediated anti-tumor responses. This combination therapy improves efficacy against non-injected tumors and long-term survival, even in large tumors.
Researchers at Waseda University developed a new nanoparticle combination therapy that effectively resuscitates trauma patients with massive hemorrhage. The therapy, using nanoparticles with hemostatic and oxygen-carrying potential, shows comparable results to conventional transfusion.
A new study has found that HIV can be detected in the central nervous system of patients on long-term antiretroviral therapy, linked to poorer cognitive performance. The discovery highlights the need to address viral mechanisms of cognitive decline in cART-treated patients.
A new combination of targeted therapies improved overall survival and objective response in patients with BRAF-mutant colorectal tumours. The BEACON CRC Phase III trial showed that triplet therapy significantly outperformed standard care, suggesting a potential replacement for chemotherapy for eligible patients.
Researchers found that a specific esmolol-epinephrine ratio can provide cardioprotection while maintaining hemodynamic activity during myocardial ischemia and reperfusion injury. This combination therapy may be beneficial in treating patients with cardiogenic shock or cardiac arrest.
A new study published in Brain suggests that neurotechnology-based therapies, such as brain-machine interfaces and robotics, can lead to largest treatment effects when tailored to individual patient needs. Personalized combination of these therapies may allow patients to continue their recovery beyond what is possible today.
Researchers at Purdue University have discovered that blue light can render MRSA bacteria defenseless against antiseptics like hydrogen peroxide. This new method uses photobleaching to reduce pigment production in the bacteria, making it a promising alternative to traditional antibiotics.
Researchers at the University of Bonn have reported significant progress in treating aggressive brain tumors like glioblastoma. Combination chemotherapy with CCNU and temozolomide significantly prolongs patients' survival time, with a notable benefit for those with methylated MGMT promoter.
Researchers have developed a more effective treatment for visceral leishmaniasis (VL) in HIV patients, combining AmBisome with miltefosine. The combination therapy achieved parasite clearance rates of up to 88% compared to 55% with monotherapy.
Research from the Abramson Cancer Center presents findings on CAR T combinations, timing of therapy, and patient access. Studies evaluate effectiveness in multiple myeloma patients, Chronic Lymphocytic Leukemia (CLL) patients, and lymphoma patients with high-risk profiles.